Edition:
United States

Aradigm Corp (ARDM.OQ)

ARDM.OQ on NASDAQ Stock Exchange Capital Market

1.33USD
21 May 2018
Change (% chg)

$-0.12 (-8.28%)
Prev Close
$1.45
Open
$1.42
Day's High
$1.42
Day's Low
$1.32
Volume
13,048
Avg. Vol
41,609
52-wk High
$7.26
52-wk Low
$1.04

Chart for

About

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery... (more)

Overall

Beta: 8.61
Market Cap(Mil.): $21.54
Shares Outstanding(Mil.): 15.17
Dividend: --
Yield (%): --

Financials

  ARDM.OQ Industry Sector
P/E (TTM): -- 223.30 32.53
EPS (TTM): -0.79 -- --
ROI: -430.54 -8.07 12.63
ROE: -- -10.87 14.50

BRIEF-Aradigm Q1 Loss Per Share $0.32

* Q1 REVENUE $1.5 MILLION VERSUS $1.7 MILLION Source text for Eikon: Further company coverage:

May 15 2018

BRIEF-Aradigm Announces EMA Has Completed Its Validation Of The MAA Submission

* ARADIGM ANNOUNCES THE EMA HAS COMPLETED ITS VALIDATION OF THE MAA SUBMISSION

Apr 05 2018

BRIEF-Aradigm Reports Q4 Loss Per Share Of $0.28

* ARADIGM ANNOUNCES FOURTH QUARTER 2017 AND FULL YEAR FINANCIAL RESULTS

Mar 23 2018

BRIEF-Aradigm Submits Marketing Authorisation Application To EMA For EU Marketing Approval Of Linhaliq

* ARADIGM SUBMITS MARKETING AUTHORISATION APPLICATION (MAA) TO EMA FOR EU MARKETING APPROVAL OF LINHALIQ IN NON-CYSTIC FIBROSIS BRONCHIECTASIS Source text for Eikon: Further company coverage:

Mar 09 2018

BRIEF-FDA Declines To Approve Aradigm's Drug Linhaliq

* ARADIGM RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA FOR LINHALIQ NDA

Jan 29 2018

BUZZ-Aradigm Corp: Ladenburg Thalmann cuts rating to 'neutral'

** Drug developer's shares plunge 42.7 pct to $1.96 premarket - top pct loser among all U.S.-listed stocks

Jan 12 2018

BRIEF-Aradigm - FDA Advisory Committee Did Not Recommend Approval For Linhaliq

* ARADIGM REPORTS RESULTS OF FDA ADVISORY COMMITTEE MEETING ON LINHALIQ‍​

Jan 11 2018

BRIEF-Boxer Capital Reports 5.9 Pct Passive Stake In Aradigm Corp As Of Nov 30

* BOXER CAPITAL LLC REPORTS 5.9 PERCENT PASSIVE STAKE IN ARADIGM CORP AS OF NOVEMBER 30 - SEC FILING Source text: (http://bit.ly/2BDnINX) Further company coverage:

Dec 11 2017

BRIEF-Aradigm Announces FDA Advisory Committee Meeting For Linhaliq

* ARADIGM ANNOUNCES FDA ADVISORY COMMITTEE MEETING FOR LINHALIQ

Dec 01 2017

Earnings vs. Estimates